Bengaluru-based biopharma leader PlasmaGen Biosciences has raised ₹150 crore in its latest funding round, valuing the company at over ₹1,500 crore. The round was led by ViNS Bioproducts, with participation from high-net-worth individuals (HNIs), family offices, pharma entrepreneurs, and existing investors.

Backed by Eight Roads Ventures, PlasmaGen has now mopped up over ₹600 crore in total funding to date, with previous investments from Fidelity’s FIL Capital Investments and F-Prime Capital.

Strengthening India’s Biopharma Self-Reliance

Founded in 2010, PlasmaGen is a “pure-play” plasma biopharma company focused on bridging the critical demand-supply gap for plasma-derived therapies in India. The company produces essential life-saving medicines, including:

• Immunoglobulin

• Albumin

• Clotting Factors

These products serve critical care, neurology, and hematology segments, where domestic availability has historically been a challenge.

Scaling the Kolar Fractionation Plant

The fresh capital is earmarked for three primary objectives:

1. International Expansion: Securing regulatory approvals and establishing distribution networks in key global markets.

2. Product Portfolio Growth: Adding new therapies to their existing line of plasma products.

3. Capacity Building: Strengthening manufacturing capabilities and leadership teams.

PlasmaGen reached a major operational milestone in 2024, commencing commercial operations at its state-of-the-art plasma fractionation facility in Kolar, Karnataka. The setup is one of only five such specialized facilities in India, positioning the company as a dominant player in the domestic manufacturing landscape.

A Cold-Chain Driven Future

While the company is eyeing overseas markets, India remains its primary focus. PlasmaGen is currently expanding its reach across hospitals and physicians via a robust cold-chain-backed distribution network to ensure the integrity of its temperature-sensitive therapies.

“With our Kolar facility now operational and reporting strong revenue growth, we are well-positioned to achieve self-reliance in plasma products for India while simultaneously entering international geographies,” the company stated in a press release.

By: Vanshika Tayal